GSK’s Breo Ellipta Gains FDA Panel Nod For Airflow Obstruction, Exacerbation Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Pulmonary-Allergy Drugs Advisory Committee recommended approval of the once-daily product for chronic obstructive pulmonary disease despite questions about the relative contribution of the combination drug’s corticosteroid component.